References
Tauschmann M, Allen JM, Wilinska ME et al (2016) Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 39:1168–1174
Blauw H, van Bon AC, Koops R et al (2016) Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab 18:671–677
Kovatchev B, Tamborlane WV, Cefalu WT, Cobelli C (2016) The artificial pancreas in 2016: a digital treatment ecosystem for diabetes. Diabetes Care 39:1123–1126
Bonfanti R, Lepore G, Bozzetto L et al (2016) Survey on the use of insulin pumps in Italy: comparison between pediatric and adult age groups (IMITA study). Acta Diabetol 53:403–412
Nørgaard K, Scaramuzza A, Bratina N et al (2013) Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther 15:273–280
Acknowledgments
We would like to thank all adolescents with type 1 diabetes who with their great enthusiasm give us the possibility to study new technologies.
Funding
The study was not funded. All patients were using MiniMed 640G insulin pump as part of their daily routine care. In Italy pumps, infusion sets and sensors are provided free of charge by regional Health Agencies (ASL).
Authors’ contributions
All authors reviewed and provided edits and comments on manuscript drafts. In addition, authors had the following responsibilities: A.S. designed the protocol, collected data, analyzed the data, and drafted the manuscript; C.A., V.C., E.P., I.R., S.To., S.Tu., G.C., P.C., L.F., L.L., D.T., and F.L. were camp physicians, contributed to study design, collected the data, and reviewed the manuscript; O.C. was the supervisor of camp activities and reviewed the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have no potential conflicts of interest relevant to this paper. However, in the previous 2 years for some of the Authors interests to disclose are as follow: A.S. received personal fees from Eli Lilly, Roche, and Sanofi for participating in advisory boards or consulting. V.C. has received personal fees for consulting from Eli Lilly and Sanofi. I.R. has received fees for consulting from Roche Diagnostics, Eli Lilly, Sanofi, and Menarini. S.To. has received personal fee for consulting from Eli Lilly. S.Tu. has received personal fees for consulting/speaker honoraria from Novo Nordisk, Sanofi Aventis, Eli Lilly, Lifescan, and Roche. F.L. has received personal fees for consulting from Eli Lilly and Roche.
Human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 [5].
Informed consent
Informed consent was obtained from all patients for being included in the study.
Additional information
Managed by Antonio Secchi.
Rights and permissions
About this article
Cite this article
Scaramuzza, A.E., Arnaldi, C., Cherubini, V. et al. Use of the predictive low glucose management (PLGM) algorithm in Italian adolescents with type 1 diabetes: CareLink™ data download in a real-world setting. Acta Diabetol 54, 317–319 (2017). https://doi.org/10.1007/s00592-016-0927-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-016-0927-0